Categories
Change Password!
Reset Password!
Only single dose of mRNA
COVID-19 vaccine may be enough to boost immune response in individuals
recovered from SARS-CoV-2
infection.
The outcomes of a latest study published in
The Journal
of Clinical Investigation raised questions regarding the use of a second mRNA vaccine in COVID-19 recovered patients.
Also, the time to attain herd immunity can be reduced if millions of vaccine
doses may be redirected to people who have not be exposed to COVID-19.
Alessio Mazzoni and researchers deduced the
effect of two doses of COVID-19 vaccination (BNT162b2) in COVID-19 recovered
compared to people who never had COVID-19, i.e. naive subjects.
The COVID-19 spike-specific T and B cell
responses, plus especially Immunoglobulin (IgG, IgA, IgM) and neutralizing
antibodies titers in 22 people who were given COVID-19 vaccine were evaluated. Eleven
out of 22 patients had a history of SARS-CoV-2 infection. Evaluations were
carried out prior to vaccination and then per week until 7 days after the
second vaccine.
Clearly, one vaccine dose was appropriate
to increase both cellular and humoral immune response in COVID-19 recovered
individuals. The administration of second dose did not provide extra
improvement. But,
the second dose was crucial in naive subjects to further boost the immune
response. These findings were further strengthened based on the serological level
in naïve (68 individuals) and COVID-19 recovered (29 individuals), with a follow-up
of 50 days after the vaccination.
The Journal of Clinical Investigation
First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in recovered COVID-19 subjects
Alessio Mazzoni et al.
Comments (0)